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Introduction. The aim of the exracranial stereotactic technique (SBRT) is the administration in few sessions of high doses of
radiation to a reduced volume adjacent to critical organs. This technique needs a very precise immobilization and a way to
reproduce it daily with ease.
Target. To explain the different immobilization systems used in radiation oncology service ICODuran Reynals since this technique
was ﬁrst used until the latest technique used today.
Methodology. We started using the technique in 2008. We have used several immobilization procedures since then. And each
treatment session quality control images were taken and analyzed to measure the deviations occurred from the longitudinal,
lateral and vertical isocenter.
Conclusions. We have observed that with the different locking systems used during the time period of 2008–2013 we were able
to gradually reduce the deviation from the isocenter. In conclusion, a good immobilization procedure assures us a more precise
treatment consisting of smaller ﬁelds and closer to organs at risk.
http://dx.doi.org/10.1016/j.rpor.2013.03.552
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Objective. To introduce the technique of SBRT in radiotherapy service.
Introduction. Extracranial stereotactic radiation therapy is a formof high-precision radiotherapy treatment using hypofractionated
ablative radiation dose, 1–5 fractions, stereotactic-techniques with 3D conformal radiotherapy (3D-CRT) or intensity modulated
radiotherapy (IMRT), image-guided-radiotherapy (IGRT) before each fraction.
Methods. In March 2012 we began the implementation of SBRT. Patient were selected if oligometástasis (controlled primary
tumor and metastasis in numbers ≤3, located in the same), life-expectancy>6 months and -PS<2. The process comprising:
1. Interventional Radiology Department inserts a ﬁducial-marker (Visicoil®, all-CT except guided ultrasound in 2 cases). Is
placed at a distance<5 cm of the metastatic lesion and the patient remains under observation 24h if metastases are lung
(no-pneumothorax), otherwise referred to its home at 6-o’clock insertion. 2. Immobilization abdominal-compressor system
Body-Pro-Lock® indexed to the treatment-table and the marking and tattooing TAC-referenced. 3. Acquisition in 4DPET/CT with
Philips-Gemini-TF gating to liver damage or CT-if pulmonary gating, both with abdominal compression system. 4D-acquired in
both the PET and the CT. Perform a takeover of CT in a situation of normal breathing. 4D acquisitions are used-to contour the
GTV-following the movement of the respiratory cycle. 4. Fuse with the planning-system PhilipsPinnacle8.0 with CT-obtained in
normal breathing. This acquisition is for outline planning treatment and risk-organs. 5. We determined ITV-and-PTV margin
expansion ranged from 3 to 5mm. 6. Treatment given in Siemens-Linear-Accelerator, -with built-imaging-equipment (ExacTrac)
being-acquired stereoscopic images that are fused to the DRR-planning and adjusts automatically to the correct position.
Results. Since March 2012 we have treated-6 patients-(4 liver-metastases and 3 lung; 1 patient twice, lung and liver-metastases),
dose 36–12Gy/session, 3 sessions/week (except the ﬁrst patient: 50–5Gy −10 sessions on alternate days). One-patient-died due
to disease progression and 5 remaining stable. Immediate-tolerance: acute toxicity, vs. 3 CTC criteria, G2-asthenia in 2 patients
and no toxicity in the rest.
Conclusions. SBRT treatment modality is a high precision, which is evolving. Its effectiveness is proven in lung carcinoma non-
small-cell, lung metastases, liver and spine. Our initial experience conﬁrms the feasibility of its application and usefulness in
our midst.
http://dx.doi.org/10.1016/j.rpor.2013.03.553
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Objective. Analyze the results of single dose RS to spinal metastases without spinal cord compression.
Methods. In our institution vertebral metastasis treatment is performed by a Novalis® LINAC (BrainLab, Germany). The Novalis®
utilizes image registration of anatomical structures such as vertebral bone in a non-invasive procedure. Images are taken on the
simulation CT, with body vacuum-bag, using infrared external ﬁducials on the patient’s skin, CT images are contouring module
on planning system (iPlan-Net.v5.1®) fussed with a volumetric T1 and T2 weighted MRI. The external ﬁducials are tracked by the
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infrared cameras of the ExacTrac® system for automatice treatment position. IGRT is performed before each treatment ﬁeld. The
6D robotic couch allows translational and rotational corrections. Sliding Windows IMRT treatment is administered with multiple
coplanar beams.
Results. FromNovember/2008 to January/2013,wehave treated 17patientswith 22 spinemetastasis, all the patients received single
18Gy, GTV is contoured as the entire body of the vertebra and/or the affected transverse and spinous processes, PTV is obtained
by expanding 2–3mm GTV. OARs dose constrains are based on RTOG-0631 protocol. The location of the vertebral metastasis
was: cervical 5, thoracic 9, lumbar 8; none of the patients have had prior radiotherapy on the treatment ﬁeld. 8 patients (47.05%)
have pain VAS≥5. With a median follow up of 17.6 months (0.5–43.5), 20 tumors had local control after treatment. No grade III
toxicity was found, total pain control was achieved in 70% of the patients, with a pain reduction in 90% (median months from
the treatment 3.8 weeks).
Conclusions. Vertebral radiosurgery is safe an accurate for spinal metastases, achieving fast and good results in pain and tumoral
control.
http://dx.doi.org/10.1016/j.rpor.2013.03.554
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Purpose. To present preliminary experience in the treatment of CNS metastases with radiosurgery, using multiple non-coplanar
arcs with RapidArc®.
Methods. From June to December 2012 ten patients were included (7 patients with single mts, 2 with two mts, and one pts with
4 mts). Mean age was 65 yo. (57–79). Primary tumour was: lung 6, breast 2, colon 1, prostate 1. ECOG distribution: 0:1; 1:5; 2:3;
3:1. Only two patients have evidence of metastases outside of CNS with minimal burden. Immobilization was performed with
thermoplastic mask and CT simulation with slices of 1.5mm. Treatment consists of 4–5 non-coplanar arcs (VMAT) with different
table rotation (0, 60, 30, 330 and 360◦). Prescription dose ranged from 12 to 18Gy. Dosimetric objectives were: 99% of PTV and 100%
of GTV must received 100% of prescription dose. Quality of treatment planning was evaluated with Paddick index, homogeneity
index and gradient index. Geometric veriﬁcation was made with cone beam CT. Median PTV was 6.6 cm3 (0.4–36 cm3).
Results. Dosimetric results: Quality index were superior compared to other techniques (cones, tomotherapy, and cyberknife).
Total treatment time (median): 29 + 8min. Clinical results: Acute toxicity: there were two case of mild hemiparesia, and one
case of headache. Local control: only one patient showed local progression. Regional control: two patients developed other
CNS metastases and were rescued with another radiosurgery, and one patient developed multiple CNS metastases requiring
holocraneal irradiation. Three patients were deceased because of disease progression. Seven patients were alive after a mean
follow-up of 17 weeks.
Conclusions. Single fraction radiosurgery with RapidArc® with multiple non-coplanar arcs showed high accuracy and quality.
Toxicity was mild and early results are comparable with other radiosurgery techniques.
http://dx.doi.org/10.1016/j.rpor.2013.03.555
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Purpose. Several recent studies have shown that a subset of patients with metastatic cancer in limited organs may beneﬁt from
metastasis-directed therapy.
Aim. We present a series on patients treated with stereotactic tomotherapy (HT), and assess the efﬁcacy and toxicity of this new
technology in the treatment of extracraneal oligometastasis.
Materials and methods. From August 2006 through July 2011, 42 consecutive patients (median age 69 years) with 1–3 metastatic
cancer sites receivedHT to all known cancer sites (lung, n=28; liver, n=12; adrenal, n=2). Twenty-seven patients (64%) had a single
lesion, 12 patients (29%) 2 lesions, and 3 patients (7%) 3 lesions. Acute toxicities were scored using the Common Terminology
Criteria version 3.0.
Results. A total of 60 lesions were treated with hypofractionated HT (median dose 39Gy [range 36–72.5]; median dose per fraction
12Gy [range, 5–20]). With a median follow-up period of 15 months (range 2–57), 1- and 2-year overall survival (OS) was 84%
and 63%, respectively; and 1- and 2-year local control (LC) was 92% and 86%, respectively. Regarding treatment-related acute
